Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
1
Historical Events
1
Regulatory Approvals
1 competitor in Relapsed Diffuse Large B-Cell Lymphoma
View Full LandscapeTarget Indication
Relapsed Diffuse Large B-Cell Lymphoma
Clinical Trial
NCT04384484Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Zynlonta
Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.